Cargando…
Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and saf...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604240/ https://www.ncbi.nlm.nih.gov/pubmed/36294300 http://dx.doi.org/10.3390/jcm11205978 |
_version_ | 1784817763797172224 |
---|---|
author | Diep, Laetitia Barbier, Vincent Doussière, Marie Touboul, Estelle Jesson, Claire Deprez, Valentine Sobhy-Danial, Jean-Marc Fardellone, Patrice Goëb, Vincent |
author_facet | Diep, Laetitia Barbier, Vincent Doussière, Marie Touboul, Estelle Jesson, Claire Deprez, Valentine Sobhy-Danial, Jean-Marc Fardellone, Patrice Goëb, Vincent |
author_sort | Diep, Laetitia |
collection | PubMed |
description | Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and safety profiles. Methods: This retrospective, observational, single-center study included RA patients who had received at least one intravenous dose of infliximab, abatacept, and/or tocilizumab. Two-year drug persistence was estimated using the Kaplan–Meier method. Efficacy profiles were assessed as changes of Disease-Activity Score-28 (DAS28)-based EULAR-criteria responses. Results: The infliximab, abatacept, and tocilizumab groups included 40, 72, and 93 patients, respectively. Their respective 2-year persistence rates were similar: 55.0%, 45.8%, and 62.4%. Tocilizumab recipients benefited from greater improvement than those given infliximab (p = 0.0005) or abatacept (p < 0.0001). For all groups combined, 93.1% of patients obtained good or moderate EULAR responses. Conclusions: Even if this retrospective work includes different biases (lack of data, recruitment bias, etc.), it highlights that the 2-year persistence rates for infliximab, abatacept, and tocilizumab in daily practice did not differ significantly, thereby confirming the long-term efficacies of these three bDMARDs. However, tocilizumab was associated with more significant DAS28 improvement at 2 years than infliximab and abatacept. |
format | Online Article Text |
id | pubmed-9604240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96042402022-10-27 Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates Diep, Laetitia Barbier, Vincent Doussière, Marie Touboul, Estelle Jesson, Claire Deprez, Valentine Sobhy-Danial, Jean-Marc Fardellone, Patrice Goëb, Vincent J Clin Med Article Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and safety profiles. Methods: This retrospective, observational, single-center study included RA patients who had received at least one intravenous dose of infliximab, abatacept, and/or tocilizumab. Two-year drug persistence was estimated using the Kaplan–Meier method. Efficacy profiles were assessed as changes of Disease-Activity Score-28 (DAS28)-based EULAR-criteria responses. Results: The infliximab, abatacept, and tocilizumab groups included 40, 72, and 93 patients, respectively. Their respective 2-year persistence rates were similar: 55.0%, 45.8%, and 62.4%. Tocilizumab recipients benefited from greater improvement than those given infliximab (p = 0.0005) or abatacept (p < 0.0001). For all groups combined, 93.1% of patients obtained good or moderate EULAR responses. Conclusions: Even if this retrospective work includes different biases (lack of data, recruitment bias, etc.), it highlights that the 2-year persistence rates for infliximab, abatacept, and tocilizumab in daily practice did not differ significantly, thereby confirming the long-term efficacies of these three bDMARDs. However, tocilizumab was associated with more significant DAS28 improvement at 2 years than infliximab and abatacept. MDPI 2022-10-11 /pmc/articles/PMC9604240/ /pubmed/36294300 http://dx.doi.org/10.3390/jcm11205978 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Diep, Laetitia Barbier, Vincent Doussière, Marie Touboul, Estelle Jesson, Claire Deprez, Valentine Sobhy-Danial, Jean-Marc Fardellone, Patrice Goëb, Vincent Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates |
title | Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates |
title_full | Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates |
title_fullStr | Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates |
title_full_unstemmed | Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates |
title_short | Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates |
title_sort | comparison of rheumatoid arthritis patients’ 2-year infliximab, abatacept, and tocilizumab persistence rates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604240/ https://www.ncbi.nlm.nih.gov/pubmed/36294300 http://dx.doi.org/10.3390/jcm11205978 |
work_keys_str_mv | AT dieplaetitia comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT barbiervincent comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT doussieremarie comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT touboulestelle comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT jessonclaire comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT deprezvalentine comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT sobhydanialjeanmarc comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT fardellonepatrice comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates AT goebvincent comparisonofrheumatoidarthritispatients2yearinfliximababataceptandtocilizumabpersistencerates |